僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain （TIGIT）. Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab （HY-P9904）, may be effective against multiple solid malignancies-most notably non-small cell lung cancer （NSCLC）